KEAP1 and non-small cell lung carcinoma: These findings suggest that dual-checkpoint inhibition may mitigate the “immune-cold” microenvironment characteristic of STK11/KEAP1-mutant NSCLC and warrant continued investigation in prospective biomarker-stratified trials (195).